LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, CKD and cancer.  

Other than cell therapy, LumiSTAR also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates. LumiSTAR’s drug screening platform can apply on phenotypic screening, drug discovery, toxicity testing, and precision/personalized medicine.